SEC Form 4 · accession 0001209191-16-111281
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Francis Willard Sarena
Officer — EVP, Gen Counsel and Secretary
Period of report
Mar 29, 2016
Accepted (ET)
Mar 31, 2016 · 6:40 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 29, 2016 | M | 4,450 | $8.49 | A | 88,284 | D | |
| Common Stock | Mar 29, 2016 | S | 4,450 | $40.00 | D | 83,834 | D | |
| Common Stock | Mar 30, 2016 | M | 5,550 | $8.49 | A | 89,384 | D | |
| Common StockF2 | Mar 30, 2016 | S | 5,550 | $40.01 | D | 83,834 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F3 | $8.49 | Mar 29, 2016 | M | 926 | D | — | Jul 13, 2021 | Common Stock | 926 | 0 | D |
| Employee Stock Option (right to buy)F3 | $8.49 | Mar 29, 2016 | M | 3,524 | D | — | Jan 1, 2022 | Common Stock | 3,524 | 10,297 | D |
| Employee Stock Option (right to buy)F3 | $8.49 | Mar 30, 2016 | M | 5,550 | D | — | Jan 1, 2022 | Common Stock | 5,550 | 4,747 | D |
Explanation of responses
- F1The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on October 27, 2015.
- F2The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.025, inclusive. The reporting person undertakes to provide to Five Prime Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4.
- F3This option is fully vested and immediately exercisable.